anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a linear concatamer of at least two non-identical DNA  sequences which, by virtue of third base redundancy of the genetic code of the codons, each encode the same polypeptide of at least 30 amino acids; wherein the concatamer comprises or consists of a nucleic acid sequence which codes for an oligomer of said polypeptides in a continous reading frame. A single invariant cysteine codon may be added to one DNA sequence to encode a polypeptide derivative with a unique unpaired cysteine. The concatamer may be fused to one or more sequences encoding one or more antigens. The DNA  sequences in the concatamer may encode the compliment C3 fragment C3d or an analogue thereof. The invention also provides an expression vector comprising the concatamer nucleic acid sequence and regulatory or other sequences for expression of any oligomeric polypeptide encoded thereby, as well as a host cell comprising the expression vector. The invention can also provide a method of inducing an immune response to an antigen in the human or animal by administering a concatamer or administering a vector. Thus the invention can provide a pharmaceutical composition in the form of a DNA vaccine.
PURPOSE:An inhibitor for blood platelet agglutination, containing pyrrole-2-car- boxylic acid, or a nontoxic salt thereof as an active constituent, having improved antiagglutination effect on blood platelets, and useful for preventing and treating thrombotic embolism, etc. CONSTITUTION:An inhibitor for blood platelet agglutination containing pyrrole-2- carboxylic acid or a nontoxic salt thereof, e.g. Na salt, K salt or Mg salt, as an active constituent. The dose thereof is 50-200mg/kg for parenteral administration and 250-1,000mg/kg for oral administration. The administration form is tablet, capsule, granule, solution, suppository, injection, etc. The inhibitor has improved inhibitory action on blood platelet agglutination, and is very useful for preventing and treating thrombotic embolism, etc.
The present invention relates to a tetrahydropalmatine dispersion tablet for treating dysmenorrhea and a method for preparing the tetrahydropalmatine dispersion tablet. The dispersion tablet comprises tetrahydropalmatine used as main material, and ten auxiliary materials, wherein the tetrahydropalmatine has the molecular formula of C21H25O4N. The specific formula and the specific preparing method are disclosed in specifications. The present invention has the advantages of convenient administration, rapid absorption, high degree of biological utilization and no adverse reaction. Medicines with large taking dosage and irritability are improved, and the dispersion tablet is convenient for old people or children to swallow. The product of the present invention is mainly used for treating diseases of gastrointestinal systems and hepatobiliary systems, and the product has favorable effects on pain reduction and pain alleviation but has poor effects on severe pain of traumas, etc. and can also be used for pain alleviation of parturition and dysmenorrhea. The soporific effect and the tranquilizing effect are favorable, and patients fall asleep in 20 to 30 minutes after taking the tablet. The effect can kept for 5 to 6 hours, and no after effect exists, so that the dispersion tablet can be used for temporary insomnia.
Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
Patients seen at the University of Texas (UT) Southwestern Wound Clinic with a diabetic foot wound will be identified, consented, and screened for the study. Upon signing consent, patients will be assigned a unique screening number. The screening number given to the first patient will be 01 and increasing sequentially with each subject screened. Screened subjects will be entered onto a screening log. Once a number is assigned it cannot be re-assigned to another subject.

At Day 0, a vascular evaluation including ABI, Sensilase, Transcutaneous oxygen measurements, and hyperspectral imaging will be performed. Monofilament Sensory Test and Vibration Perception Threshold(VPT) test will also be performed at day 0.Patients will undergo standard of care wound debridement. Tissue samples will be taken routinely as standard of care. A wound assessment will be performed, including the debridement as standard of care, wound measurements, and digital photos. Gene expression and bacterial analysis will be performed on tissue samples. After tests are performed, patient will receive topical oxygen therapy using the Transcutaneous O2 device with moist wound dressings. Moist wound dressings are used as standard of care. Patient will receive instructions to continue treatment at home.

Patient will return for an appointment at days 7, 14, and 21, where vascular assessment (Sensilase, Transcutaneous oxygen measurements, Hyperspectral imaging) ,wound assessment (wound measurements, digital photos and acetate tracings) and tissue sampling will be performed following standard of care debridement, Patient will cease topical oxygen treatment at day 21, and study will be concluded.
Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
BACKGROUND: Splenic artery aneurysms (SAAs) are rare but seem to have higher incidence in patients with portal hypertension (PH). The present article aims to analyze the interference of PH in the natural history of these aneurysms.
METHODS: This was a retrospective study of data recorded prospectively. Between January 2000 and December 2019, all SAAs patients in follow-up at a tertiary institution were selected for analysis. Primary end point was to analyze the presentation and evolution of SAAs in patients with PH, and secondary was to identify cumulative rates of freedom from rupture, interventions, and survival in this group, during a 10-year follow-up.
RESULTS: In total, 96 patients were identified with SAAs, 79 (82.29%) did not have PH and 17 (17.7%) had this comorbidity. Among the demographic characteristics, the patients with SAAs and PH were significantly younger (52 years [standard deviation {SD} 13.3] versus 61.9 years [SD 12.2] [P = 0.05]) and had lower number of pregnancies (1.1 pregnancies [SD 1.2] versus 3.37 pregnancies [SD 2.3] [P = 0.03]). Patients with PH had a higher cumulative rate of surgical intervention throughout follow-up (up to 75.6% in 10 years) when compared to patients without PH, with 36.9% intervention rate in 10 years of follow-up. Patients with PH had larger diameter at diagnosis (35 mm, SD 27.3) compared to patients without PH (22.6 mm, SD 16.1), P = 0.008. However, there were no statistical differences in the relative growth rate, in aneurysmal rupture rate throughout follow-up, as well as in survival over the years, between the groups.
CONCLUSIONS: The patients with SAAs and PH are significantly younger, have larger SAA diameters at diagnosis and have a higher cumulative rate of surgical intervention throughout follow-up in 10 years, despite the relative growth rate being similar to that of patients without PH.
A composition is for the targeted knockout of a gene on double-stranded DNA in a biological cell. A method is for the targeted knockout of a gene on double-stranded DNA in a biological cell. A preparation includes a biological cell prepared in vitro. The biological cell includes a gene on double-stranded DNA, which is knocked-out in a targeted manner. A kit is for the targeted knockout of a gene on double-stranded DNA in a biological cell. Another method is for treating a subject afflicted with a disease associated with a mutated gene. Nucleic acid molecules can be a component of the composition and methods.
Acne keloidalis is a primary scarring alopecia characterized by longstanding inflammation in the scalp causing keloid-like scar formation and hair loss. Histologically, acne keloidalis is characterized by mixed leukocytic infiltrates in the acute stage followed by a granulomatous reaction and extensive fibrosis in the later stages. To further explore its pathogenesis, bulk RNA sequencing, single-cell RNA sequencing, and spatial transcriptomics were applied to occipital scalp biopsy specimens of lesional and adjacent no-lesional skin in patients with clinically active disease. Unbiased clustering revealed 19 distinct cell populations, including 2 notable populations: POSTN+ fibroblasts with enriched extracellular matrix signatures and SPP1+ myeloid cells with an M2 macrophage phenotype. Cell communication analyses indicated that fibroblasts and myeloid cells communicated by SPP1 signaling networks in lesional skin. A reverse transcriptomics in silico approach identified corticosteroids as possessing the capability to reverse the gene expression signatures of SPP1+ myeloid cells and POSTN+ fibroblasts. Intralesional corticosteroid injection greatly reduced SPP1 and POSTN gene expression as well as acne keloidalis disease activity. Spatial transcriptomics and immunofluorescence staining verified microanatomic specificity of SPP1+ myeloid cells and POSTN+ fibroblasts with disease activity. In summary, the communication between POSTN+ fibroblasts and SPP1+ myeloid cells by SPP1 axis may contribute to the pathogenesis of acne keloidalis.
Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiotherapy and receive amifostine as in stratum I. Patients also receive 3 courses of cisplatin as before.
The invention discloses an electrochemical method for preparing a fluorine-containing hydroxyapatite/zirconia transition coating on the surface of medical titanium. The method comprises the steps that: electro-deposition is carried in an electrolytic tank with a three-electrode system, wherein a medical titanium chip is adopted as a working electrode; a Zr(OH)4 plating is deposited in a zirconyl nitrate solution with a certain concentration and a certain pH value, wherein the deposition current is 11.1mA and the deposition time is 40s; a fluorine-containing hydroxyapatite (FHA) plating is deposited in an electrolyte which has a certain concentration and a certain pH value and which is composed of calcium nitrate, ammonium dihydrogen phosphate, and sodium fluoride, wherein the deposition current is 0.8mA and the deposition time is 3600s; and vacuum sintering is carried out under a temperature of 450 DEG C, such that the FHA/ZrO2 transition coating is obtained. According to the invention, fluorine partially substitutes hydroxyl group in apatite, fluorine ions are smaller than hydroxyl groups, and FHA lattice constant is small, such that FHA solubility is lower than HA. A coating morphology is changed from a micron-level chrysanthemum petal shape into a nano-level cone shape. With an antibacterial effect of F ions, dental caries can also be prevented. ZrO2 serves as a transition layer between the titanium substrate and the FHA coating, and the bonding strength between the FHA/ZrO2 transition coating and the Ti substrate is greatly improved. The bonding strength between the FHA/ZrO2 transition coating and the titanium substrate is high, a physiological solubility resistance is high, and antibacterial performance is good. The provided product has certain potential to be developed into an oral medical material with good development prospect.
Diabetes in adolescence is associated with deterioration in glycaemic control and self-care, resulting in increased risk of long-term complications. Although psychosocial factors are recognized as playing an important part in these changes and therefore in clinical management, there are few indicators from research studies of practical, effective interventions. Motivational interviewing is a counselling approach designed to facilitate decision-making about behaviour change. It has been shown to be effective in a variety of clinical settings, including diabetes care in an adult population. In a BDA-funded pilot study of motivational interviewing with adolescents, our group has shown that the intervention improves glycaemic control (glycosylated haemoglobin), at least in the short-term. This study aims to replicate and extend the findings of the pilot study in a multicentre, randomised, controlled trial over a longer intervention period with a larger sample. The intervention will be monitored to facilitate analysis and description of key components. Other psychological variables thought to be of significance in the self-care of adolescents with diabetes will be measured. If the results indicate that this is a successful intervention, the method has potential to be disseminated and applied within routine clinical practice.
Older children more than 8 years usually have a poor prognosis, especially without treatment. Apart from the age at diagnosis and surgery, the severity of femoral head flattening and the signs of "head at risk" are also associated with the final clinical outcome. The current surgical treatment options, including proximal femoral varus osteotomy, innominate osteotomy, lateral shelf acetabuloplasty,triple pelvic osteotomy, and Chiari pelvic osteotomy have proved to be effective in covering the femoral head within the acetabulum. To promote the coverage of the femoral head, shelf acetabuloplasty directly increases the size of the acetabulum by implanting graft bone to the lateral rim. When used as salvage surgery, it may provide relief from pain and benefit the involved hip via femoral head flattening, especially in older children. It also improves the spherical remodeling of the femoral head and acetabulum by stimulating lateral acetabular growth. Lateral shelf acetabuloplasty is able to increase the coverage of the femoral head, which is an important tissue for remodeling and preventing further femoral head deformation.
In two trials, VANCOCIN 125 mg orally four times daily for 10 days was evaluated in 266 adult subjects with C. difficile-associated diarrhea (CDAD). Enrolled subjects were 18 years of age or older and received no more than 48 hours of treatment with oral VANCOCIN or oral/intravenous metronidazole in the 5 days preceding enrollment. CDAD was defined as ≥3 loose or watery bowel movements within the 24 hours preceding enrollment, and the presence of either C. difficile toxin A or B, or pseudomembranes on endoscopy within the 72 hours preceding enrollment. Subjects with fulminant C. difficile disease, sepsis with hypotension, ileus, peritoneal signs or severe hepatic disease were excluded. 

Efficacy analyses were performed on the Full Analysis Set (FAS), which included randomized subjects who received at least one dose of VANCOCIN and had any post-dosing investigator evaluation data (N=259; 134 in Trial 1 and 125 in Trial 2). 

The demographic profile and baseline CDAD characteristics of enrolled subjects were similar in the two trials. VANCOCIN-treated subjects had a median age of 67 years, were mainly white (93%), and male (52%). CDAD was classified as severe (defined as 10 or more unformed bowel movements per day or WBC ≥15000/mm3) in 25% of subjects, and 47% were previously treated for CDAD. 

Efficacy was assessed by using clinical success, defined as diarrhea resolution and the absence of severe abdominal discomfort due to CDAD, on Day 10. An additional efficacy endpoint was the time to resolution of diarrhea, defined as the beginning of diarrhea resolution that was sustained through the end of the prescribed active treatment period. 

The results for clinical success for VANCOCIN-treated subjects in both trials are shown in Table 2. 

The median time to resolution of diarrhea was 5 days and 4 days in Trial 1 and Trial 2, respectively. For subjects older than 65 years of age, the median time to resolution was 6 days and 4 days in Trial 1 and Trial 2, respectively. In subjects with diarrhea resolution at end-of-treatment with VANCOCIN, recurrence of CDAD during the following four weeks occurred in 25 of 107 (23%) and 18 of 102 (18%) in Trial 1 and Trial 2, respectively. 

Restriction Endonuclease Analysis (REA) was used to identify C. difficile baseline isolates in the BI group. In Trial 1, the Vancocin-treated subjects were classified at baseline as follows 31 (23%) with BI strain, 69 (52%) with non-BI strain, and 34 (25%) with unknown strain. Clinical success rates were 87% for BI strain, 81% for non-BI strain, and 76% for unknown strain. In subjects with diarrhea resolution at end-of-treatment with VANCOCIN, recurrence of CDAD during the following four weeks occurred in 7 of 26 subjects with BI strain, 12 of 56 subjects with non-BI strain, and 6 of 25 subjects with unknown strain.
All patients meeting entrance criteria, injected with 99m Tc-TM, and having one or more lymph nodes removed for which the pathologist confirms the type (lymph node versus non-lymph node) and contents (e.g., tumor cells) of the excised tissues will comprise the intent-to-treat population (ITT). This definition also carries over to the lymph nodes; i.e., nodes used for the ITT analysis must come from patients included in the ITT population. The ITT population will serve as the analysis population for all efficacy endpoints, unless indicated otherwise in the description of analyses.
The oral LD 50s for single doses of IMURAN in mice and rats are 2500 mg/kg and 400 mg/kg, respectively. Very large doses of this antimetabolite may lead to marrow hypoplasia, bleeding, infection, and death. About 30% of IMURAN is bound to serum proteins, but approximately 45% is removed during an 8-hour hemodialysis. 14 A single case has been reported of a renal transplant patient who ingested a single dose of 7500 mg IMURAN. The immediate toxic reactions were nausea, vomiting, and diarrhea, followed by mild leukopenia and mild abnormalities in liver function. The white blood cell count, SGOT, and bilirubin returned to normal 6 days after the overdose.
PURPOSE: A composition for improving of skin wrinkle and for enhancing of elasticity of skin is provided to make canadine promote collagen synthesis of fibroblast of skin and improve skin wrinkle as well as elasticity of skin by suppressing activation of collagenase to be used as pharmaceutical composition, external preparation for skin, cosmetic composition or as health nutritional food. CONSTITUTION: The pharmaceutical composition for improving of wrinkled skin and enhancing of elasticity of skin comprises a chemical formula 1 as an active ingredient. The active ingredient is included as 0.0001 through 10 weight% in comparison to whole composition. The external preparation for improving of wrinkled skin and for enhancing of elasticity includes chemical formula 1 as an active ingredient. The cosmetic composition for improving of wrinkled skin and for enhancing of elasticity includes chemical formula 1 as an active ingredient. The nutritional health food for improving of wrinkled skin and for enhancing of elasticity includes chemical formula 1 as an active ingredient.
Contactless vital signs and stress measurement. Eligible participants will agree to have a 1.5-minute facial video recorded using an iPad. Video will be processed through a specialized algorithm to obtain BP, HR, RR, HRV and stress index. measurements.
Distinguishing clinical subgroups for patients suffering with diseases characterized by a wide phenotypic spectrum is essential for developing precision therapies. Patients with gain-of-function (GOF) variants in the SCN8A gene exhibit substantial clinical heterogeneity, viewed historically as a linear spectrum ranging from mild to severe. To test for hidden clinical subgroups, we applied two machine-learning algorithms to analyze a dataset of patient features collected by the International SCN8A Patient Registry. We used two research methodologies: a supervised approach that incorporated feature severity cutoffs based on clinical conventions, and an unsupervised approach employing an entirely data-driven strategy. Both approaches found statistical support for three distinct subgroups and were validated by correlation analyses using external variables. However, distinguishing features of the three subgroups within each approach were not concordant, suggesting a more complex phenotypic landscape. The unsupervised approach yielded strong support for a model involving three partially ordered subgroups rather than a linear spectrum. Application of these machine-learning approaches may lead to improved prognosis and clinical management of individuals with SCN8A GOF variants and provide insights into the underlying mechanisms of the disease.
The use of alkanols (I), having a 6-10C linear, branched or cyclic chain, is claimed in the production of medicaments for treating disorders associated with cystic fibrosis transmembrane conductance (CFTR) channel dysfunction in humans or animals. ACTIVITY : Antiinflammatory; antiasthmatic; cardiant; nephrotropic. MECHANISM OF ACTION : Cystic fibrosis transmembrane conductance (CFTR) channel activator. In tests in chinese hamster ovary cells expressing recombinant human CFTR protein (CHO-CFTR-(+)), 1-octanol (Ia) activated the CFTR channel at concentrations of 0.3-5 mM (EC 50value ca. 0.5 mM), this effect being completely inhibited by the known specific CFTR inhibitor glibenclamide (100 mu M). (Ia) had no activating effect on CHO cells not expressing CFTR.
Each participant will have an individualized assessment with plan and goals set at the program intake visit. Program components will include: Physical Activity, Nutrition, Emotional Well-being, Cardiovascular Risk, Survivorship, and other items individualized to the participant as needed (e.g., tobacco cessation). The 12-week program will alternate between group and individual sessions each week. Individualized plans will be reviewed every two weeks at the participant individual sessions.